Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, ...

BTIG raised the firm’s price target on Verona Pharma (VRNA) to $77 from $51 and keeps a Buy rating on the shares. The company’s Q4 ...

Wells Fargo analyst Tiago Fauth raised the firm’s price target on Verona Pharma (VRNA) to $74 from $64 and keeps an Overweight rating on the ...

Verona Pharma (VRNA) stock in focus as company reports early sales for Q4 and 2024 thanks to its lung disease therapy ...

Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...

Sanctuary Advisors LLC acquired a new stake in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) in the third quarter, ...

On Oct. 22, Caligan announced that it has taken a position in Verona Pharma. Verona Pharma is a clinical stage, pre-revenue, biopharmaceutical company that focuses on the development and ...

Verona Pharma plc (NASDAQ:VRNA – Get Free Report)’s share price dropped 2.5% during mid-day trading on Tuesday . The company traded as low as $45.64 and last traded at $45.83. Approximately 105,374 ...

Verona Pharma (NASDAQ:VRNA) just reported results for the second quarter of 2024. Verona Pharma reported earnings per share of -80 cents. This was below the analyst estimate for EPS of -29 cents.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...